

UC Irvine

UC Irvine Previously Published Works

Title

Pharmacologic epigenetic modulators of alkaline phosphatase in chronic kidney disease.

Permalink

<https://escholarship.org/uc/item/62170585>

Journal

Current opinion in nephrology and hypertension, 29(1)

ISSN

1062-4821

Authors

Haarhaus, Mathias
Gilham, Dean
Kulikowski, Ewelina
[et al.](#)

Publication Date

2020

DOI

10.1097/mnh.0000000000000570

Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed



Pharmacologic epigenetic modulators of alkaline phosphatase in chronic kidney disease

Mathias Haarhaus^{a,b,c}, Dean Gilham^d, Ewelina Kulikowski^d, Per Magnusson^b, and Kamyar Kalantar-Zadeh^{e,f,g}

Purpose of review

In chronic kidney disease (CKD), disturbance of several metabolic regulatory mechanisms cause premature ageing, accelerated cardiovascular disease (CVD), and mortality. Single-target interventions have repeatedly failed to improve the prognosis for CKD patients. Epigenetic interventions have the potential to modulate several pathogenetic processes simultaneously. Alkaline phosphatase (ALP) is a robust predictor of CVD and all-cause mortality and implicated in pathogenic processes associated with CVD in CKD.

Recent findings

In experimental studies, epigenetic modulation of ALP by microRNAs or bromodomain and extraterminal (BET) protein inhibition has shown promising results for the treatment of CVD and other chronic metabolic diseases. The BET inhibitor apabetalone is currently being evaluated for cardiovascular risk reduction in a phase III clinical study in high-risk CVD patients, including patients with CKD (ClinicalTrials.gov Identifier: NCT02586155). Phase II studies demonstrate an ALP-lowering potential of apabetalone, which was associated with improved cardiovascular and renal outcomes.

Summary

ALP is a predictor of CVD and mortality in CKD. Epigenetic modulation of ALP has the potential to affect several pathogenetic processes in CKD and thereby improve cardiovascular outcome.

Keywords

alkaline phosphatase, apabetalone, bromodomain and extraterminal inhibition, chronic kidney disease, epigenetic, microRNA, vascular calcification

INTRODUCTION

Chronic kidney disease (CKD) is a state of imbalance of several important physiologic regulatory mechanisms, among them mineral balance, acid–base balance, nutritional balance, and energy balance, resulting in accelerated cardiovascular disease (CVD) and mortality. In addition, CKD is also associated with chronic inflammation and resembles a model for premature ageing [1,2]. In CKD, numerous pathways are upregulated that are associated with immunity and inflammation, oxidative stress, endothelial dysfunction, vascular calcification, and coagulation [3]. Pharmacologic epigenetic modulation has the advantage of targeting several disease-related processes simultaneously. Due to its expression in multiple tissues and organs, which is upregulated in response to different pathogenic stimuli, alkaline phosphatase (ALP, EC 3.1.3.1) may be a suitable target for epigenetic modulation (Fig. 1).

^aDivision of Renal Medicine and Baxter Novum, Karolinska Institutet, Karolinska University Hospital, Stockholm, ^bDepartment of Clinical Chemistry, and Department of Experimental and Clinical Medicine, Linköping University, Linköping, ^cDiaverum Sweden AB, Stockholm, Sweden, ^dResverlogix Corp. Research and Development, Calgary, Alberta, Canada, ^eDivision of Nephrology and Hypertension, Harold Simmons Center for Kidney Disease Research and Epidemiology, University of California Irvine, Orange, ^fNephrology Section, Tibor Rubin Veterans Affairs Medical Center, Long Beach and ^gDepartment of Epidemiology, UCLA Fielding School of Public Health, Los Angeles, California, USA

Correspondence to Mathias Haarhaus, MD, PhD, Division of Renal Medicine and Baxter Novum, Karolinska Institutet, Karolinska University Hospital, SE-14186 Stockholm, Sweden. Tel: +46 58580000; e-mail: mathias.loberg-haarhaus@sll.se

Curr Opin Nephrol Hypertens 2020, 29:4–15

DOI:10.1097/MNH.0000000000000570

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

KEY POINTS

- Circulating ALP is a robust risk marker for CVD and all-cause mortality in the general population and in CKD.
- ALP is ubiquitously expressed and is involved in several pathophysiological processes associated with cardiovascular complications in CKD, for example vascular calcification, chronic inflammation, oxidative stress, and fibrosis.
- BET inhibitors and microRNAs are epigenetic modulators with the potential to simultaneously target several different pathogenic mechanisms upregulated in chronic diseases.
- The novel epigenetic modulator apabetalone targets pathogenic processes associated with the induction of ALP and improves cardiovascular prognosis in high-risk patients, including patients with CKD, while lowering circulating ALP activity.

ALKALINE PHOSPHATASE IN HEALTH AND DISEASE

ALP is a ubiquitously expressed enzyme that catalyses the hydrolytic removal of phosphate groups from biochemical compounds [4]. Four different isozymes are known in humans. The tissue-nonspecific isozyme (TNALP) is expressed in different organs, for example, bone, liver, kidneys, brain, cardiovascular system, and leukocytes, whereas tissue-specific isozymes are expressed in the intestine (IALP), the placenta, and the testis (germ cell ALP) [5]. In most healthy individuals, circulating total ALP activity is comprised of approximately 50% of bone-specific isoforms of TNALP (BALP) and an equal percentage of liver-specific TNALP isoforms. However, in patients with blood groups B and O, IALP can contribute up to 10% of the circulating ALP activity. In individuals with blood group A, IALP contributes less than 3% of total ALP activity, as




FIGURE 1. Alkaline phosphatase is ubiquitously expressed; however, the contribution of alkaline phosphatase from different tissues to the circulating alkaline phosphatase activity may vary. Under healthy conditions, liver and bone isoforms of tissue-nonspecific isozyme alkaline phosphatase comprise approximately 50% each of the total circulating alkaline phosphatase activity. Intestine alkaline phosphatase can comprise up to 10% of the circulating alkaline phosphatase activity in individuals with blood group B or O, but less than 3% in individuals with blood group A. Circulating alkaline phosphatase predicts disease-related outcomes, for example cardiovascular disease or mortality, but to which extent alkaline phosphatase derived from specific tissues contributes to the total circulating alkaline phosphatase activity in pathologic conditions remains largely undetermined. Designed by Macrovector and Brgfx - Freepik.com.

blood group A red cells bind IALP in the circulation. ALP is an ectoenzyme attached to the outer layer of cell membranes. It is released into circulation as a soluble homodimer and cleared from the circulation via hepatic asialoglycoprotein receptors after desialylation by circulating neuraminidase [6–8].

TNALP is involved in the regulation of biomineralization, inflammation, oxidative stress and endothelial dysfunction, fibrosis, and cellular hypertrophy [9,10–12]. TNALP dephosphorylates compounds of the extracellular matrix quite unspecifically. Known biological functions of ALP include the inactivation of calcification inhibitors, the dephosphorylation of nucleotides in purinergic signaling, the activation of matrix metalloproteinases (MMPs), and the local regulation of vitamin B6 metabolism (Fig. 2). IALP contributes to the regulation of the gut microbiome, nutrient uptake, and the systemic immune response [5].

ALP is present in many species including humans, and is routinely applied as a marker for liver disease or bone turnover; however, until recently, its biologic relevance was poorly understood. Similar to the evolutionary science behind

the emergence of the C-reactive protein (CRP) from an inflammatory modulator to now a novel CVD marker, over the past 2 decades, ALP, too, has been emerging with newly discovered roles in biological homeostasis [9]. Emerging evidence suggests that circulating ALP is a strong predictor of adverse cardiovascular outcome and all-cause mortality [9]. In spite of being a novel cardiovascular risk marker and potential therapeutic target for cardiovascular risk, no clinical stage therapeutics aimed at lowering serum ALP are available to date.

Alkaline phosphatase and biomineralization

Biomineralization is regulated by a complex interplay of calcification promoters and inhibitors. In CKD, disturbance of this interplay is common and can cause extensive soft-tissue calcification such as medial artery calcification or calcification of atherosclerotic plaques. ALP is essential for bone mineralization, as demonstrated by hypophosphatasia, a hereditary disease with loss-of-function mutations of the *ALPL* gene that encodes TNALP [13]. In addition, ALP plays a central role in pathological




FIGURE 2. Summary of mechanisms linking dephosphorylation by alkaline phosphatase to normal and pathophysiological processes. LPS, lipopolysaccharides; MMP, metalloproteinase; OPN, osteopontin; Pi, phosphate; PL, pyridoxal; PLP, pyridoxalphosphate; PPI, pyrophosphate.

soft-tissue calcification [14,15]. ALP is actively enhanced in matrix vesicles derived from mineralization-competent cells. These vesicles function as nuclei for matrix mineralization. The process is similar in physiologically mineralizing tissues, such as bone and dentin, and in pathological soft-tissue calcification. ALP promotes the propagation of matrix mineralization by dephosphorylation of mineralization inhibitors such as pyrophosphate and the phosphoprotein osteopontin, and by generation of inorganic phosphate, rendering a more procalcific extracellular milieu [16–18]. A role in the regulation of additional phosphoproteins in the extracellular matrix can be speculated. Matrix Gla protein (MGP) is one of the most important physiological mineralization inhibitors [19]. Its activity is determined by post-translational phosphorylation in addition to vitamin K-dependent carboxylation [20,21]. The effect of MGP inhibition by pharmacological vitamin K antagonists on the propagation of medial artery calcification and calcific uremic arteriolopathy in CKD is well known [22,23]. Lower circulating levels of the nonphosphorylated form of MGP are associated with vascular calcification and mortality in dialysis patients, independent of its carboxylation status [24]. However, the mechanisms of MGP dephosphorylation are yet unknown and a role for ALP in this process can only be hypothesized.

Alkaline phosphatase and fibrosis

A novel mechanism has been suggested for ALP in fibrosis and cardiovascular fibrocalcification, which is a feature of congestive heart failure [25]. The upregulation of ALP in cardiac myocytes leads to increased fibrosis via dephosphorylation of metalloproteinases 2 and 9 [26]. Indeed, increased circulating ALP activities have been observed in CKD patients with myocardial hypertrophy and congestive heart failure [27–29]. Further, ALP in bronchoalveolar lavage has been identified as a marker of pulmonary fibrosis, connecting ALP to fibrotic processes in the lung [30].

Alkaline phosphatase and inflammation

Several mechanisms link ALP to inflammation. Circulating ALP correlates well with circulating CRP, and ALP has been suggested as a component of the hepatic acute phase reaction [31]. Also, circulating IALP is enhanced in inflammatory conditions [32]. However, CRP and inflammatory cytokines have an inhibitory effect on ALP activity in osteoblasts [33,34] as circulating CRP was only associated with total ALP, not BALP, in a large cohort of dialysis patients [35], suggesting an extra-skeletal source for

the increased circulating ALP activity during inflammation. In contrast to the effect of inflammation on ALP in bone, inflammatory mediators can increase ALP activity in vascular smooth muscle cells (VSMCs) and mesenchymal stem cells [36,37], which is concordant with the clinical finding of opposing effects of inflammation on bone versus vascular mineralization in CKD [38]. ALP modulates the cellular inflammatory response via purinergic signaling by contributing to the enzymatic conversion of proinflammatory extracellular adenosine triphosphate to anti-inflammatory adenosine [39]. ALP is also expressed by inflammatory cells in the vascular wall, and may mediate a link between inflammation and vascular calcification, commonly seen in the atherosclerotic plaque and in diseases of the metabolic syndrome, such as type 2 diabetes mellitus and CKD [40–43].

Sepsis-induced inflammation can cause acute kidney injury and loss of renal function that leads to morbidity and mortality [44]. Serum ALP predicts infection-related mortality [45] and has been proposed as a component of a clinical prediction model for bacteremia in CKD stage 5D patients [46]. Circulating ALP has the potential to inactivate endotoxins and other highly phosphorylated proinflammatory compounds [31,32]. Intestinal ALP detoxifies lipopolysaccharide (LPS) to reduce its inflammatory properties and interaction with Toll-like receptors and prevents inflammation in zebrafish in response to the gut microbiota [47]. Indeed Resolvin E1-induced intestinal ALP promotes resolution of inflammation through LPS detoxification [48]. This concept is being challenged in clinical trials. For example, in patients with acute kidney injury and sepsis, injection of recombinant ALP promoted a decrease in all-cause mortality, supporting a physiological role for ALP in mitigating the deleterious and morbid actions arising from sepsis [49]. Hence, similar to CRP, there is a biologically plausible role for increased levels of ALP under such pathologic circumstance, which may elicit maladaptive consequences. IALP may also exert a protective effect against inflammation-induced complications of diabetes mellitus type 1, such as CVD or diabetic nephropathy [50].

Alkaline phosphatase and oxidative stress

Increased oxidative stress is associated with adverse cardiovascular outcomes [51]. Oxidative stress induces ALP and calcification in calcifying vascular cells [52]. Increased oxidative stress is also associated with osteoporosis [53] because mineralization is inhibited in osteoblasts [52]. The reduction of cardiovascular oxidative stress in CKD patients by

exercise treatment is associated with a reduction of circulating ALP [54]. However, the origin of the increased serum ALP activity in patients with oxidative stress has yet to be determined.

Alkaline phosphatase and hypertension

ALP contributes to regulation of hypertension and vascular tone. Inhibition of ALP in isolated perfused kidneys and in experimental animals *in vivo* decreased the hypertensive blood pressure (BP) response to norepinephrine [55]. The effect is partially explained by the role of ALP in purinergic signaling and increased adenosine production. Circulating ALP activity is inversely correlated to maximal vasodilatory response to acetylcholine, indicative of endothelial dysfunction [56]. An additional mechanism linking ALP to BP control is the association with arterial stiffness [57], possibly explained by vascular calcification [58]. A contribution of ALP to increased fibrotic transformation of capacity arteries can also be speculated [59].

Alkaline phosphatase and cognitive impairment

Circulating ALP is associated with impaired cognition [60–62]. Cognitive impairment is a serious complication in ageing and CKD. Underlying abnormalities include neurodegenerative processes and impaired microcirculation. In Alzheimer's disease, ALP in the brain and circulation is inversely correlated with cognitive function, and dephosphorylation of tau has been suggested as a putative pathomechanism [63]. Increased circulating ALP is also associated with cerebral small vessel disease, a hallmark of vascular cognitive impairment [64]. ALP contributes to the regulation of gamma aminobutyrate and other neurotransmitters [65]. The association of reduced circulating ALP after parathyroidectomy in CKD patients with improved cognition suggests a possible therapeutic implication for ALP lowering in cognitive impairment [66].

Alkaline phosphatase in chronic kidney disease

In CKD, circulating ALP is commonly used in conjunction with parathyroid hormone for the approximation of bone turnover due to its association with bone formation [10,67]. In the absence of liver disease, variations in total ALP typically arise from BALP, and can identify extremes of high and low bone turnover [68]. Furthermore, circulating ALP is a better predictor of incident fractures in dialysis patients than bone mineral density [69]. Circulating

ALP is also a strong and independent predictor of mortality and cardiovascular complications in CKD [9[¶]]. In non-CKD populations, the association between ALP and inflammation is predictive of mortality [35]. In contrast, circulating BALP levels in patients with advanced CKD are an even stronger predictor of mortality than total ALP [70]. This could be due to its association with the extensive vascular calcification arising in patients with CKD on dialysis [71]. As all of the pathomechanisms discussed above are upregulated in CKD [3], the contribution of ALP to the increased CKD-related mortality, cardiovascular complications, and impaired cognition is presumably multifactorial.

REGULATION OF *ALPL* GENE EXPRESSION

Human TNALP is encoded by the *ALPL* gene (accession number, NM_000478), which is located on the short arm of chromosome 1, 1p36.12 [72–74]. The *ALPL* gene exceeds 50 kb and comprises 12 exons. The first exon is part of the 5'-untranslated region of the TNALP mRNA, which consists of either exon 1A or 1B that respond to different promoters and results in two mRNAs, each encoding an identical polypeptide, but with different 5'-untranslated regions [75]. The expression of TNALP is ubiquitous; however, transcription of the two variants of exon 1 results in cell-specific and tissue-specific expression. One of these transcripts is termed 'bone *ALPL* transcript' in active osteoblasts comprising exon 1A, whereas exon 1B is driven by a separate promoter active in liver and kidney tissues [75,76].

The regulation of *ALPL* expression is best studied in osteoblast-like cells. Bone formation by cells from the osteoblast lineage and functional actions, for example, biomineralization, involve multiple developmental signals such as hormones, growth factors, cytokines, Wingless-related integration site (WNT) ligands, and bone morphogenetic proteins. In addition, there are also several transcription factors that regulate the expression of a variety of osteoblast-specific genes expressing proteins pivotal for biomineralization, for example, collagen type I, bone-specific alkaline phosphatase, and osteocalcin [77]. The bone essential transcription factor runt-related transcription factor 2 (Runx2) has been identified as the master regulator for osteoblast differentiation [78]. Osterix (*Osx*; *Sp7* gene), a zinc finger-containing transcription factor with a Runx2-binding sequence, is also essential for osteoblast differentiation and bone mineralization. *Osx* is not expressed in Runx2-deficient mice, whereas the expression of Runx2 is not affected in *Osx*-deficient mice [79], which implies that *Osx* regulates osteoblast differentiation downstream of Runx2 [80].

Other key transcription factors involved in osteoblast differentiation are the homeobox gene *Msx2* and members of the distal-less homeobox (*Dlx*) family. *Msx2* represses the expression of *ALPL* by directly binding to its promoter, whereas *Dlx5* activates *ALPL* expression by interfering with the action of *Msx2* [81]. *Dlx3* is another potent regulator of *Runx2* activation during osteogenic differentiation [82]. It has also been demonstrated that overexpression of *Dlx2* has no effect on *RUNX2*, *DLX5*, and *MSX2* expression upon osteogenic induction, but stimulated *ALPL* and osteocalcin expression [83]. Thus, *Dlx2* may directly upregulate *ALPL* to promote osteoblastogenesis.

EPIGENETIC REGULATION OF ALKALINE PHOSPHATASE

The term *Epigenotype* was coined in 1942 by Waddington who concluded that ‘between genotype and phenotype lies a whole complex of development processes’ [84]. The modern definition of epigenetics includes modifications of DNA and associated proteins, not involving changes to the underlying DNA sequence, that are influenced by the environment and maintained during cell division that cause stable changes in gene expression [85[¶]]. The main epigenetic factors are DNA methylation, posttranslational changes of histones, and higher order chromatin structure. Post translational modifications of histones impact chromatin structure, accessibility, and recruitment of transcription machinery to dictate whether genes are switched on or off. These dynamic modifications orchestrate cellular responses to environmental, developmental, or metabolic stimuli through modification of the transcriptome. However, epigenetics can underlie dysregulated gene expression in disease states including cancer [86] and pathological inflammatory processes [87]. Enzymes or proteins that generate or interact with epigenetic alterations can be classified as writers, erasers, or readers, depending on whether they add, remove, or recognize a posttranslational modification (Fig. 3).

Histone acetylation

Histone acetylation is associated with open chromatin structure, accessibility for transcription factor binding, and active transcription [88[¶]]. Histone acetylation impacts TNALP expression. Histone deacetylase inhibitors (HDACi) increase chromatin acetylation. *In vitro*, HDACi-induced expression of *ALPL* and promoted osteogenic differentiation of human mesenchymal stem cells [89]. Mechanistically, histone acetylation has been

associated with the regulation of bone morphogenetic proteins, WNT signaling, and *RUNX2* induction [90]. Whether acetylation directly impacts promoters of *ALPL* expression is an area of ongoing research.

DNA methylation

Studies have demonstrated that the *ALPL* promoter A1E is highly methylated [91]. Delgado-Calle *et al.* [92], demonstrated that DNA methylation has an important role in the modulation of *ALPL* expression in human osteoblast-like cells. They showed an inverse relationship between the methylation status of a CpG island extending from –579 to +836 bp of the *ALPL* gene including the promoter region, which implies that epigenetic regulation by DNA demethylation strongly enhances TNALP expression and activity [92]. In VSMC, both phosphate and hydroxyapatite nanocrystals modulate DNA methylation, which results in an increased ALP activity and the induction of an osteoblast-like phenotype [93,94].

MicroRNAs

Long noncoding RNAs and microRNAs (miRNAs) are also key epigenetic factors that are involved in posttranscriptional gene regulation [77,95[¶]]. The miRNAs are small noncoding single-stranded RNA molecules, approximately 18–25 nucleotides, that inhibit protein synthesis by binding to the 3'-untranslated region of mRNA to block protein translation and/or modulate mRNA stability. It has been estimated, through computational predictions, that more than 50% of all human protein-coding genes are potentially regulated by miRNAs [96]. Bone-regulating miRNAs play a key role in osteogenic differentiation and signaling pathways involved in osteogenesis [77,95[¶],97,98]. The key transcription factors *Runx2* and *Osx* are downregulated by numerous miRNAs in pluripotent mesenchymal cells to suppress the bone phenotype in nonosseous cells and tissues [77,99].

Some miRNAs have been found to suppress and promote distinct signaling pathways related with osteogenic differentiation [95[¶],100[¶]]. Reduced mRNA expression for collagen I, TNALP, and osteocalcin has been found while overexpressing miR-375, thus suggesting that miR-375 is able to suppress osteogenic differentiation by targeting *Runx2* [101]. Overexpression of miR-133a-5p has also been reported to inhibit *ALPL* expression and mineralization through targeting *Runx2* [102]. Li *et al.* [103], demonstrated that miR-216a promoted osteoblast differentiation and enhanced bone formation.




FIGURE 3. Chromatin is comprised of DNA and proteins that generate a compact structure critical for packaging and stability of eukaryotic chromosomes. The primary protein components are histones, around which the DNA is wound to form a nucleosome. Epigenetics involves covalent modifications to chromatin that does not affect the underlying DNA sequence. Covalent modifications to chromatin impact both chromatin structure and recruitment of transcription complexes that, in effect, switch genes on or off. These dynamic epigenetic modifications are carried out by adding (writing) and removing (erasing) posttranslational modifications, followed by ‘reading’, which dictates gene expression and eventual phenotypic response.

PHARMACOLOGIC EPIGENETIC INTERVENTIONS TARGETING ALKALINE PHOSPHATASE

MicroRNAs

Given the ubiquitous expression of ALP, its central role in biomineralization and the high incidence of vascular calcification in patients with CKD, it is reasonable to explore pharmacologic epigenetic modulation of ALP as a potential therapeutic measure aimed at the prevention of cardiovascular complications in CKD [9[¶]]. Recent evidence indicates that miRNAs are deregulated in CKD – mineral and bone disorder [104]. Experimental studies support the concept that miRNAs are potential targets to ameliorate vascular calcification [100[¶]]. According to the miRBase version 22, sequences of 2656 mature human miRNAs have been catalogued so far [105]. Hence, it is a challenging task to include

most of the miRNAs that have been investigated over the years in this review. However, recent data demonstrate that phosphate-induced aortic calcification trigger miRNA modulation by upregulating miR-200c, miR-155 and miR-322, whereas miR-708 and miR-331 were downregulated [106[¶]]. Other miRNAs that are involved in vascular calcification, thus potential treatment targets, are miR-29a/b, miR-30d/e, miR-125b, miR-135a, miR-143, miR-145, miR-204, miR223 and miR-762 [107]. Most of these miRNAs target the two main transcription factors Runx2 and Osx that influence TNALP activity and biomineralization. Undoubtedly, miRNAs have a key role in regulating the progression of vascular calcification; however, the high abundance of miRNAs requires extended large-scale epigenome-wide studies to fully exploit the potential of epigenetic regulation by miRNAs for novel therapeutic approaches to ameliorate vascular calcification.




FIGURE 4. Chromatin acetylation is an epigenetic modification associated with open chromatin structure and active transcription. Bromodomain and extraterminal proteins are ‘chromatin readers’ that bind acetylated lysine on histones or transcription factors via two tandem bromodomains 1 and 2 and recruit transcriptional machinery (e.g. positive transcription elongation factor and RNA polymerase II) to drive expression of bromodomain and extraterminal sensitive genes. Apabetalone is an orally available small molecule inhibitor of bromodomain and extraterminal bromodomains that causes bromodomain and extraterminal protein release from chromatin and, as a consequence, downregulation of bromodomain and extraterminal sensitive gene transcription. Apabetalone preferentially targets bromodomain 2 (represented by yellow halo), a characteristic that differentiates it from pan-bromodomain and extraterminal inhibitors that bind bromodomains 1 and 2 with equal affinity.

Bromodomain and extraterminal inhibition

Bromodomain and extraterminal (BET) proteins BRD2, BRD3, BRD4, and BRDT are chromatin readers that not only bind acetylated lysine on histone tails and transcription factors via bromodomains 1 and 2, but also recruit transcriptional machinery to regulate gene expression [108]. BET inhibitors (BETi) block the interaction of BET proteins with acetylated histones or transcription factors to impact expression of target genes [88[¶]]. Apabetalone is an orally available BETi in clinical development for treatment of CVD. It preferentially binds bromodomain 2 in BET proteins (Fig. 4), which distinguishes it from pan-BETi that target bromodomains 1 and 2 with

equal affinity [109]. In clinical trials, apabetalone treatment reduced major adverse cardiac events (MACE) in patients with CVD, and was associated with 44% relative risk reduction on top of standard of care [110[¶]]. The reduction of MACE by apabetalone was associated with a reduction of serum ALP, independent of traditional cardiovascular risk factors and inflammation [111[¶]]. Studies showed this drug concurrently modulated factors that promote atherosclerotic plaque stabilization and MACE reduction. HDL cholesterol increased [110[¶],112], while the complement cascade, acute phase reaction, and mediators of vascular inflammation were suppressed [113,114].

In CKD patients with a history of CVD, apabetalone treatment improved kidney function and reduced circulating levels of ALP [115]. Mechanistically, apabetalone downregulated *ALPL* expression in primary human hepatocytes and VSMC [116[¶]], and as a consequence, reduced TNALP protein levels and enzymatic activity. Small molecule inhibitors of TNALP have been evaluated as a therapeutic for vascular calcification [14], however, apabetalone may be the first clinical stage molecule to modify TNALP production. *In vitro*, apabetalone opposed calcification of VSMCs cultured in osteogenic conditions through an epigenetic mechanism involving BRD4 that suppressed induction of procalcific genes, including *RUNX2* and *ALPL* [116[¶]].

A single dose of apabetalone in CKD stage 4–5 patients rapidly resulted in reduction of numerous inflammatory cytokines, including IL-6 [2]. In the same study, proteomic profiling of more than 1300 plasma proteins predicted several immune and inflammatory pathways were activated in patients with impaired kidney function, including nuclear factor κ B (NF- κ B), IL-6, or bone morphogenetic protein signaling. These canonical pathways were downregulated with one dose of apabetalone, which would favourably impact progression of renal impairment and associated vascular calcification.

Bromodomain and extraterminal inhibition in metabolic bone disorders: implication for renal osteodystrophy

Distinct preclinical models of metabolic bone diseases have demonstrated that BETi do not diminish bone structure or mechanical properties, and may instead increase bone volume and restore mechanical strength [117–120]. These studies show that beneficial effects of BETi on bone disorders stems from anti-inflammatory effects, as well as epigenetic modulation of key factors in bone remodelling, including TNALP. *N*-methylpyrrolidone (NMP) is a U.S. Food and Drug Administration-approved drug excipient identified as a bioactive BETi [121]. Studies with NMP in preclinical models of bone degeneration have positioned BETi as a pharmacologic strategy for the prevention or treatment of bone diseases characterized by excessive bone resorption. Numerous studies have demonstrated BETi suppresses inflammatory responses mediated by TNF α and NF- κ B [3,122–124]. NMP promoted growth of mineralized bone that was blocked by TNF α and recovered TNF α -inhibited expression of essential osteoblastic genes, including *ALPL*, *RUNX2* and *SP7/Osterix* [125]. In addition, NMP promoted bone regeneration by enhancing BMP2 signaling in osteoblasts [126] and inhibited osteoclast differentiation

to attenuate bone resorption induced by receptor activator of NF- κ B ligand [127]. NMP was shown to increase osteoblast viability during hypoxia, and countered hypoxia-mediated downregulation of key genes involved in mineralization, including *ALPL* [128]. Mechanistically, the NMP treatment was protective in maintaining osteoblast differentiation during hypoxia in part by inhibiting NF- κ B signaling. NMP preserved bone mineral density and quality of bones in ovariectomized rats [121], essentially ameliorating estrogen depletion-induced osteoporosis. Results were verified in similar studies using *N,N*-dimethylacetamide [127], or the more potent BETi JQ1, where treatment actually reversed bone loss induced by estrogen deficiency [117]. These data imply that BETi therapy can increase bone mass and improve bone turnover in inflammatory bone disorders and potentially in CKD.

CONCLUSION

Circulating ALP is a robust and independent risk marker for CVD and mortality in the general population and in CKD. The ubiquitous expression of ALP and its involvement in several pathophysiologic processes associated with CVD, bone disease, CKD progression, and cognitive dysfunction renders it suitable for multifactorial epigenetic interventions. Positive results from clinical studies with the novel BETi apabetalone implicate a role for ALP as a possible novel cardiovascular treatment target. Experimental studies with additional BETis and miRNAs suggest a wider therapeutic potential for epigenetic modulation of ALP. Further research is required to definitively establish ALP as a clinical treatment target levels and to elucidate the effect of lowering of serum ALP towards specific targets levels on clinical outcomes.

Acknowledgements

P.M. is supported by ALF grants Region Östergötland, Sweden. K.K.-Z. is supported by the NIDDK grants R01-DK095668 and K24-DK091419 as well as philanthropic grants from Mr Harold Simmons, Mr Louis Chang, Dr Joseph Lee and AVEO.

Financial support and sponsorship

None.

Conflicts of interest

M.H. is a member of the renal clinical advisory board of Resverlogix Inc. and an employee of Diaverum Sweden, AB. He has received consultancy and speaker honoraria from Resverlogix and Amgen. D.G. and E.K. are employees of Resverlogix. K.K.-Z. is a member of the renal clinical advisory board of Resverlogix. P.M. has no conflict of interest related to this article.

REFERENCES AND RECOMMENDED READING

Papers of particular interest, published within the annual period of review, have been highlighted as:

- of special interest
- of outstanding interest

1. Stenvinkel P, Larsson TE. Chronic kidney disease: a clinical model of premature aging. *Am J Kidney Dis* 2013; 62:339–351.
 2. Kooman JP, Kotanko P, Schols AM, *et al.* Chronic kidney disease and premature ageing. *Nat Rev Nephrol* 2014; 10:732–742.
 3. Wasiaik S, Tsujikawa LM, Halliday C, *et al.* Benefit of apabetalone on plasma proteins in renal disease. *Kidney Int Rep* 2018; 3:711–721.
 4. Millan J. Mammalian alkaline phosphatase: from biology to applications in medicine and biotechnology. Weinheim: Wiley; 2006.
 5. Buchet R, Millan JL, Magne D. Multisystemic functions of alkaline phosphatases. *Methods Mol Biol* 2013; 1053:27–51.
 6. Anh DJ, Eden A, Farley JR. Quantitation of soluble and skeletal alkaline phosphatase, and insoluble alkaline phosphatase anchor-hydrolase activities in human serum. *Clin Chim Acta* 2001; 311:137–148.
 7. Anh DJ, Dimai HP, Hall SL, Farley JR. Skeletal alkaline phosphatase activity is primarily released from human osteoblasts in an insoluble form, and the net release is inhibited by calcium and skeletal growth factors. *Calcif Tissue Int* 1998; 62:332–340.
 8. Magnusson P, Sharp CA, Farley JR. Different distributions of human bone alkaline phosphatase isoforms in serum and bone tissue extracts. *Clin Chim Acta* 2002; 325:59–70.
 9. Haarhaus M, Brandenburg V, Kalantar-Zadeh K, *et al.* Alkaline phosphatase: ■ a novel treatment target for cardiovascular disease in CKD. *Nat Rev Nephrol* 2017; 13:429–442.
- A comprehensive discussion of the link between serum alkaline phosphatase (ALP), mortality and cardiovascular disease (CVD) in chronic kidney disease and the general population.
10. Sardiwal S, Magnusson P, Goldsmith DJ, Lamb EJ. Bone alkaline phosphatase in CKD-mineral bone disorder. *Am J Kidney Dis* 2013; 62:810–822.
 11. Schuetz KB, McKinsey TA. TNAP: a new player in cardiac fibrosis? Focus on 'Tissue-nonspecific alkaline phosphatase as a target of sFRP2 in cardiac fibroblasts'. *Am J Physiol Cell Physiol* 2015; 309:C137–C138.
 12. Gan XT, Taniai S, Zhao G, *et al.* CD73-TNAP crosstalk regulates the hypertrophic response and cardiomyocyte calcification due to alpha1 adrenoceptor activation. *Mol Cell Biochem* 2014; 394:237–246.
 13. Whyte MP, Simmons JH, Moseley S, *et al.* Asfotase alfa for infants and young children with hypophosphatasia: 7 year outcomes of a single-arm, open-label, phase 2 extension trial. *Lancet Diabetes Endocrinol* 2019; 7:93–105.
 14. Sheen CR, Kuss P, Narisawa S, *et al.* Pathophysiological role of vascular smooth muscle alkaline phosphatase in medial artery calcification. *J Bone Miner Res* 2015; 30:824–836.
 15. Haarhaus M, Arqvist HJ, Magnusson P. Calcifying human aortic smooth muscle cells express different bone alkaline phosphatase isoforms, including the novel B1x isoform. *J Vasc Res* 2013; 50:167–174.
 16. Millan JL. The role of phosphatases in the initiation of skeletal mineralization. *Calcif Tissue Int* 2013; 93:299–306.
 17. Halling Linder C, Ek-Rylander B, Krumpel M, *et al.* Bone alkaline phosphatase and tartrate-resistant acid phosphatase: potential co-regulators of bone mineralization. *Calcif Tissue Int* 2017; 101:92–101.
 18. Uhlin F, Fernstrom A, Knapen MHJ, *et al.* Long-term follow-up of biomarkers of vascular calcification after switch from traditional hemodialysis to online hemodiafiltration. *Scand J Clin Lab Invest* 2019; 79:174–181.
 19. Back M, Aranyi T, Cancela ML, *et al.* Endogenous calcification inhibitors in the prevention of vascular calcification: a consensus statement from the COST action EuroSoftCalcNet. *Front Cardiovasc Med* 2018; 5:196.
 20. Schurgers LJ, Spronk HM, Skepper JN, *et al.* Posttranslational modifications regulate matrix Gla protein function: importance for inhibition of vascular smooth muscle cell calcification. *J Thromb Haemost* 2007; 5:2503–2511.
 21. O'Young J, Liao Y, Xiao Y, *et al.* Matrix Gla protein inhibits ectopic calcification by a direct interaction with hydroxyapatite crystals. *J Am Chem Soc* 2011; 133:18406–18412.
 22. Nigwekar SU. Calciphylaxis. *Curr Opin Nephrol Hypertens* 2017; 26:276–281.
 23. Schurgers LJ, Teunissen KJ, Knapen MH, *et al.* Novel conformation-specific antibodies against matrix gamma-carboxyglutamic acid (Gla) protein: under-carboxylated matrix Gla protein as marker for vascular calcification. *Arterioscler Thromb Vasc Biol* 2005; 25:1629–1633.
 24. Schlieper G, Westenfeld R, Kruger T, *et al.* Circulating nonphosphorylated carboxylated matrix gla protein predicts survival in ESRD. *J Am Soc Nephrol* 2011; 22:387–395.
 25. Lin H, Angeli M, Chung KJ, *et al.* sFRP2 activates Wnt/beta-catenin signaling in cardiac fibroblasts: differential roles in cell growth, energy metabolism, and extracellular matrix remodeling. *Am J Physiol Cell Physiol* 2016; 311:C710–C719.
 26. Martin S, Lin H, Ejimadu C, Lee T. Tissue-nonspecific alkaline phosphatase as a target of sFRP2 in cardiac fibroblasts. *Am J Physiol Cell Physiol* 2015; 309:C139–C147.
 27. Koyama-Nakamura M, Mizobuchi M, Kaneko K, *et al.* Myocardial SPECT images in incident hemodialysis patients without ischemic heart disease. *Ther Apher Dial* 2015; 19:575–581.
 28. Nasri H, Baradaran A. Close association between parathyroid hormone and left ventricular function and structure in end-stage renal failure patients under maintenance hemodialysis. *Bratisl Lek Listy* 2004; 105:368–373.
 29. Ortega O, Rodriguez I, Hinojosa J, *et al.* Serum alkaline phosphatase levels and left ventricular diastolic dysfunction in patients with advanced chronic kidney disease. *Nephron Extra* 2011; 1:283–291.
 30. Capelli A, Lusuadi M, Cerutti CG, Donner CF. Lung alkaline phosphatase as a marker of fibrosis in chronic interstitial disorders. *Am J Respir Crit Care Med* 1997; 155:249–253.
 31. Pike AF, Kramer NI, Blaauw BJ, *et al.* A novel hypothesis for an alkaline phosphatase 'rescue' mechanism in the hepatic acute phase immune response. *Biochim Biophys Acta* 2013; 1832:2044–2056.
 32. Lalles JP. Intestinal alkaline phosphatase: novel functions and protective effects. *Nutr Rev* 2014; 72:82–94.
 33. Cho JJ, Choi KH, Oh CH, *et al.* Effects of C-reactive protein on bone cells. *Life Sci* 2016; 145:1–8.
 34. Huang RL, Yuan Y, Tu J, *et al.* Opposing TNF-alpha/IL-1beta- and BMP-2-activated MAPK signaling pathways converge on Runx2 to regulate BMP-2-induced osteoblastic differentiation. *Cell Death Dis* 2014; 5:e1187.
 35. Filipowicz R, Greene T, Wei G, *et al.* Associations of serum skeletal alkaline phosphatase with elevated C-reactive protein and mortality. *Clin J Am Soc Nephrol* 2013; 8:26–32.
 36. Lee HL, Woo KM, Ryoo HM, Baek JH. Tumor necrosis factor-alpha increases alkaline phosphatase expression in vascular smooth muscle cells via MSX2 induction. *Biochem Biophys Res Commun* 2010; 391:1087–1092.
 37. Ding J, Ghali O, Lencel P, *et al.* TNF-alpha and IL-1beta inhibit RUNX2 and collagen expression but increase alkaline phosphatase activity and mineralization in human mesenchymal stem cells. *Life Sci* 2009; 84:499–504.
 38. Viaene L, Behets GJ, Heye S, *et al.* Inflammation and the bone-vascular axis in end-stage renal disease. *Osteoporos Int* 2016; 27:489–497.
 39. Rader BA. Alkaline phosphatase, an unconventional immune protein. *Front Immunol* 2017; 8:897.
 40. Tsirpanlis G. Is inflammation the link between atherosclerosis and vascular calcification in chronic kidney disease? *Blood Purif* 2007; 25:179–182.
 41. Shanmugham LN, Petrarca C, Castellani ML, *et al.* IL-1beta induces alkaline phosphatase in human phagocytes. *Arch Med Res* 2007; 38:39–44.
 42. Shioi A, Katagi M, Okuno Y, *et al.* Induction of bone-type alkaline phosphatase in human vascular smooth muscle cells: roles of tumor necrosis factor-alpha and oncostatin M derived from macrophages. *Circ Res* 2002; 91:9–16.
 43. Collin J, Gossel M, Matsuo Y, *et al.* Osteogenic monocytes within the coronary circulation and their association with plaque vulnerability in patients with early atherosclerosis. *Int J Cardiol* 2015; 181:57–64.
 44. Poston JT, Koyner JL. Sepsis associated acute kidney injury. *BMJ* 2019; 364:k4891.
 45. Hwang SD, Kim SH, Kim YO, *et al.* Serum alkaline phosphatase levels predict infection-related mortality and hospitalization in peritoneal dialysis patients. *PLoS One* 2016; 11:e0157361.
 46. Sasaki S, Hasegawa T, Kawarazaki H, *et al.* Development and validation of a clinical prediction rule for bacteremia among maintenance hemodialysis patients in outpatient settings. *PLoS One* 2017; 12:e0169975.
 47. Bates JM, Akerlund J, Mitige E, Guillemin K. Intestinal alkaline phosphatase detoxifies lipopolysaccharide and prevents inflammation in zebrafish in response to the gut microbiota. *Cell Host Microbe* 2007; 2:371–382.
 48. Campbell EL, MacManus CF, Kominsky DJ, *et al.* Resolvin E1-induced intestinal alkaline phosphatase promotes resolution of inflammation through LPS detoxification. *Proc Natl Acad Sci U S A* 2010; 107:14298–14303.
 49. Pickkers P, Mehta RL, Murray PT, *et al.* Effect of human recombinant alkaline phosphatase on 7-day creatinine clearance in patients with sepsis-associated acute kidney injury: a randomized clinical trial. *JAMA* 2018; 320:1998–2009.
 50. Lassenius MI, Fogarty CL, Blaut M, *et al.* Intestinal alkaline phosphatase at the crossroad of intestinal health and disease – a putative role in type 1 diabetes. *J Intern Med* 2017; 281:586–600.
 51. Yang X, Li Y, Li Y, *et al.* Oxidative stress-mediated atherosclerosis: mechanisms and therapies. *Front Physiol* 2017; 8:600.
 52. Mody N, Parhami F, Sarafian T, Demer L. Oxidative stress modulates osteoblastic differentiation of vascular and bone cells. *Free Radic Biol Med* 2001; 31:509–519.
 53. Cervellati C, Bonaccorsi G, Cremonini E, *et al.* Oxidative stress and bone resorption interplay as a possible trigger for postmenopausal osteoporosis. *Biomed Res Int* 2014; 2014:569563.
 54. Wilund KR, Tomayko EJ, Wu PT, *et al.* Intradialytic exercise training reduces oxidative stress and epicardial fat: a pilot study. *Nephrol Dial Transplant* 2010; 25:2695–2701.
 55. Jackson EK, Zhang Y, Cheng D. Alkaline phosphatase inhibitors attenuate renovascular responses to norepinephrine. *Hypertension* 2017; 69:484–493.
 56. Peticone F, Peticone M, Maio R, *et al.* Serum alkaline phosphatase negatively affects endothelium-dependent vasodilation in naive hypertensive patients. *Hypertension* 2015; 66:874–880.

57. Manghat P, Souleimanova I, Cheung J, *et al.* Association of bone turnover markers and arterial stiffness in predialysis chronic kidney disease (CKD). *Bone* 2011; 48:1127–1132.
58. Sigrist M, Taal M, Bungay P, McIntyre C. Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease. *Clin J Am Soc Nephrol* 2007; 2:1241–1248.
59. Jiang L, Zhang J, Monticone RE, *et al.* Calpain-1 regulation of matrix metalloproteinase 2 activity in vascular smooth muscle cells facilitates age-associated aortic wall calcification and fibrosis. *Hypertension* 2012; 60:1192–1199.
60. Brown WR, Thore CR. Review: cerebral microvascular pathology in ageing and neurodegeneration. *Neuropathol Appl Neurobiol* 2011; 37:56–74.
61. Vasantharekha R, Priyanka HP, Swarnalingam T, *et al.* Interrelationship between Mini-Mental State Examination scores and biochemical parameters in patients with mild cognitive impairment and Alzheimer's disease. *Geriatr Gerontol Int* 2017; 17:1737–1745.
62. Kellett KA, Williams J, Vardy ER, *et al.* Plasma alkaline phosphatase is elevated in Alzheimer's disease and inversely correlates with cognitive function. *Int J Mol Epidemiol Genet* 2011; 2:114–121.
63. Kellett KA, Hooper NM. The role of tissue nonspecific alkaline phosphatase (TNAP) in neurodegenerative diseases: Alzheimer's disease in the focus. *Subcell Biochem* 2015; 76:363–374.
64. Ryu WS, Lee SH, Kim CK, *et al.* High serum alkaline phosphatase in relation to cerebral small vessel disease. *Atherosclerosis* 2014; 232:313–318.
65. Coburn SP. Vitamin B-6 metabolism and interactions with TNAP. *Subcell Biochem* 2015; 76:207–238.
66. Chou FF, Chen JB, Hsieh KC, Liou CW. Cognitive changes after parathyroidectomy in patients with secondary hyperparathyroidism. *Surgery* 2008; 143:526–532.
67. Haarhaus M, Fernstrom A, Magnusson M, Magnusson P. Clinical significance of bone alkaline phosphatase isoforms, including the novel B1x isoform, in mild to moderate chronic kidney disease. *Nephrol Dial Transplant* 2009; 24:3382–3389.
68. Haarhaus M, Monier-Faugere MC, Magnusson P, Malluche HH. Bone alkaline phosphatase isoforms in hemodialysis patients with low versus nonlow bone turnover: a diagnostic test study. *Am J Kidney Dis* 2015; 66:99–105.
69. Iimori S, Mori Y, Akita W, *et al.* Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients—a single-center cohort study. *Nephrol Dial Transplant* 2012; 27:345–351.
70. Drechsler C, Verduijn M, Pilz S, *et al.* Bone alkaline phosphatase and mortality in dialysis patients. *Clin J Am Soc Nephrol* 2011; 6:1752–1759.
71. Yan J, Li L, Zhang M, *et al.* Circulating bone-specific alkaline phosphatase and abdominal aortic calcification in maintenance hemodialysis patients. *Biomark Med* 2018; 12:1231–1239.
72. Swallow DM, Povey S, Pankar M, *et al.* Mapping of the gene coding for the human liver/bone/kidney isozyme of alkaline phosphatase to chromosome 1. *Ann Hum Genet* 1986; 50:229–235.
73. Smith M, Weiss MJ, Griffin CA, *et al.* Regional assignment of the gene for human liver/bone/kidney alkaline phosphatase to chromosome 1p36.1-p34. *Genomics* 1988; 2:139–143.
74. Weiss MJ, Ray K, Henthorn PS, *et al.* Structure of the human liver/bone/kidney alkaline phosphatase gene. *J Biol Chem* 1988; 263:12002–12010.
75. Matsuura S, Kishi F, Kajii T. Characterization of a 5'-flanking region of the human liver/bone/kidney alkaline phosphatase gene: two kinds of mRNA from a single gene. *Biochem Biophys Res Commun* 1990; 168:993–1000.
76. Studer M, Terao M, Gianni M, Garattini E. Characterization of a second promoter for the mouse liver/bone/kidney-type alkaline phosphatase gene: cell and tissue specific expression. *Biochem Biophys Res Commun* 1991; 179:1352–1360.
77. Lian JB, Stein GS, van Wijnen AJ, *et al.* MicroRNA control of bone formation and homeostasis. *Nat Rev Endocrinol* 2012; 8:212–227.
78. Otto F, Thornell AP, Crompton T, *et al.* Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. *Cell* 1997; 89:765–771.
79. Nakashima K, Zhou X, Kunkel G, *et al.* The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. *Cell* 2002; 108:17–29.
80. Komori T. Regulation of proliferation, differentiation and functions of osteoblasts by Runx2. *Int J Mol Sci* 2019; 20:1694.
81. Shirakabe K, Terasawa K, Miyama K, *et al.* Regulation of the activity of the transcription factor Runx2 by two homeobox proteins, Msx2 and Dlx5. *Genes Cells* 2001; 6:851–856.
82. Hassan MQ, Tare RS, Lee SH, *et al.* BMP2 commitment to the osteogenic lineage involves activation of Runx2 by DLX3 and a homeodomain transcriptional network. *J Biol Chem* 2006; 281:40515–40526.
83. Zhang J, Zhang W, Dai J, *et al.* Overexpression of Dlx2 enhances osteogenic differentiation of BMSCs and MC3T3-E1 cells via direct upregulation of Osteocalcin and Alp. *Int J Oral Sci* 2019; 11:12.
84. Waddington CH. The epigenotype. 1942. *Int J Epidemiol* 2012; 41:10–13.
85. Feinberg AP. The key role of epigenetics in human disease prevention and mitigation. *N Engl J Med* 2018; 378:1323–1334.
86. Pfister SX, Ashworth A. Marked for death: targeting epigenetic changes in cancer. *Nat Rev Drug Discov* 2017; 16:241–263.
87. Raghuraman S, Donkin I, Verstehey S, *et al.* The emerging role of epigenetics in inflammation and immunometabolism. *Trends Endocrinol Metab* 2016; 27:782–795.
88. Cochran AG, Conery AR, Sims RJ 3rd. Bromodomains: a new target class for drug development. *Nat Rev Drug Discov* 2019; 18:609–628.
- Comprehensive summary of the evidence for bromodomain and extraterminal (BET) proteins as novel therapeutic targets for epigenetic therapy.
89. Cho HH, Park HT, Kim YJ, *et al.* Induction of osteogenic differentiation of human mesenchymal stem cells by histone deacetylase inhibitors. *J Cell Biochem* 2005; 96:533–542.
90. Li SJ, Kao YH, Chung CC, *et al.* HDAC I inhibitor regulates RUNX2 transactivation through canonical and noncanonical Wnt signaling in aortic valvular interstitial cells. *Am J Transl Res* 2019; 11:744–754.
91. Escalante-Alcalde D, Recillas-Targa F, Hernandez-Garcia D, *et al.* Retinoic acid and methylation cis-regulatory elements control the mouse tissue nonspecific alkaline phosphatase gene expression. *Mech Dev* 1996; 57:21–32.
92. Delgado-Calle J, Sanudo C, Sanchez-Verde L, *et al.* Epigenetic regulation of alkaline phosphatase in human cells of the osteoblastic lineage. *Bone* 2011; 49:830–838.
93. Ha SW, Jang HL, Nam KT, Beck GR Jr. Nano-hydroxyapatite modulates osteoblast lineage commitment by stimulation of DNA methylation and regulation of gene expression. *Biomaterials* 2015; 65:32–42.
94. Montes de Oca A, Madueño J, Martínez J, *et al.* High phosphate-induced calcification is related to SM22alpha promoter methylation in vascular smooth muscle cells. *J Bone Miner Res* 2010; 25:1996–2005.
95. van Meurs JB, Boer CG, Lopez-Delgado L, Riancho JA. Role of epigenomics in bone and cartilage disease. *J Bone Miner Res* 2019; 34: 215–230.

The article discusses the relevance of epigenomics for the pathogenesis of bone diseases.

96. Taipaleenmaki H. Regulation of bone metabolism by microRNAs. *Curr Osteoporos Rep* 2018; 16:1–12.
97. Hackl M, Heilmeyer U, Weilner S, Grillari J. Circulating microRNAs as novel biomarkers for bone diseases – complex signatures for multifactorial diseases? *Mol Cell Endocrinol* 2016; 432:83–95.
98. Makitie RE, Hackl M, Niinimäki R, *et al.* Altered MicroRNA profile in osteoporosis caused by impaired WNT signaling. *J Clin Endocrinol Metab* 2018; 103:1985–1996.
99. Chen Q, Liu W, Sinha KM, *et al.* Identification and characterization of microRNAs controlled by the osteoblast-specific transcription factor Osterix. *PLoS One* 2013; 8:e58104.
100. Feng Q, Zheng S, Zheng J. The emerging role of microRNAs in bone remodeling and its therapeutic implications for osteoporosis. *Biosci Rep* 2018; 38:BSR20180453.

Discussion of the role of microRNAs (miRNAs) in bone physiology and in skeletal disorders, including implications for therapeutic use.

101. Du F, Wu H, Zhou Z, Liu YU. microRNA-375 inhibits osteogenic differentiation by targeting runt-related transcription factor 2. *Exp Ther Med* 2015; 10:207–212.
102. Zhang W, Wu Y, Shiozaki Y, *et al.* miRNA-133a-5p inhibits the expression of osteoblast differentiation-associated markers by targeting the 3' UTR of RUNX2. *DNA Cell Biol* 2018; 37:199–209.
103. Li H, Li T, Fan J, *et al.* miR-216a rescues dexamethasone suppression of osteogenesis, promotes osteoblast differentiation and enhances bone formation, by regulating c-Cbl-mediated PI3K/AKT pathway. *Cell Death Differ* 2015; 22:1935–1945.
104. Metzinger-Le Meuth V, Burtsey S, Maitrias P, *et al.* microRNAs in the pathophysiology of CKD-MBD: biomarkers and innovative drugs. *Biochim Biophys Acta Mol Basis Dis* 2017; 1863:337–345.
105. Kozomara A, Birgaoanu M, Griffiths-Jones S. miRBase: from microRNA sequences to function. *Nucleic Acids Res* 2019; 47:D155–D162.
106. Fakhry M, Skafi N, Fayyad-Kazan M, *et al.* Characterization and assessment of potential microRNAs involved in phosphate-induced aortic calcification. *J Cell Physiol* 2018; 233:4056–4067.

The article discusses the role of miRNAs as a novel link between phosphate and vascular calcification.

107. Goettsch C, Hutcheson JD, Aikawa E. MicroRNA in cardiovascular calcification: focus on targets and extracellular vesicle delivery mechanisms. *Circ Res* 2013; 112:1073–1084.
108. Filipkopoulos P, Picaud S, Mangos M, *et al.* Histone recognition and large-scale structural analysis of the human bromodomain family. *Cell* 2012; 149:214–231.
109. McLure KG, Gesner EM, Tsujikawa L, *et al.* RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist. *PLoS One* 2013; 8:e83190.
110. Nicholls SJ, Ray KK, Johansson JO, *et al.* Selective BET protein inhibition with apabetalone and cardiovascular events: a pooled analysis of trials in patients with coronary artery disease. *Am J Cardiovasc Drugs* 2018; 18:109–115.

The report is the first clinical indication that the BET inhibitor apabetalone can reduce cardiovascular events in CVD patients on top of standard of care.

111. Haarhaus M, Ray KK, Nicholls SJ, *et al.* Apabetalone lowers serum alkaline phosphatase and improves cardiovascular risk in patients with cardiovascular disease. *Atherosclerosis* 2019; 290:59–65.

This is the first clinical report of an association of pharmacologic lowering of serum ALP activity with improved cardiovascular outcome.

112. Gilham D, Wasiaik S, Tsujikawa LM, *et al.* RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease. *Atherosclerosis* 2016; 247:48–57.
113. Tsujikawa LM, Fu L, Das S, *et al.* Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism. *Clin Epigenetics* 2019; 11:102.
114. Wasiaik S, Gilham D, Daze E, *et al.* Downregulation of the complement cascade in vitro, in mice and in patients with cardiovascular disease by the BET protein inhibitor apabetalone (RVX-208). *J Cardiovasc Transl Res* 2017; 10:337–347.
115. Kulikowski E, Halliday C, Johansson J, *et al.* Apabetalone mediated epigenetic modulation is associated with favorable kidney function and alkaline phosphatase profile in patients with chronic kidney disease. *Kidney Blood Press Res* 2018; 43:449–457.
116. Gilham D, Tsujikawa LM, Sarsons CD, *et al.* Apabetalone downregulates factors and pathways associated with vascular calcification. *Atherosclerosis* 2019; 280:75–84.
- The article is the first demonstration that BET proteins are involved in epigenetic changes leading to calcification of vascular smooth muscle cells, a process ameliorated with BET inhibitors.
117. Baud'huin M, Lamoureux F, Jacques C, *et al.* Inhibition of BET proteins and epigenetic signaling as a potential treatment for osteoporosis. *Bone* 2017; 94:10–21.

118. Lamoureux F, Baud'huin M, Rodriguez Calleja L, *et al.* Selective inhibition of BET bromodomain epigenetic signalling interferes with the bone-associated tumour vicious cycle. *Nat Commun* 2014; 5:3511.
119. Meng S, Zhang L, Tang Y, *et al.* BET inhibitor JQ1 blocks inflammation and bone destruction. *J Dent Res* 2014; 93:657–662.
120. Park-Min KH, Lim E, Lee MJ, *et al.* Inhibition of osteoclastogenesis and inflammatory bone resorption by targeting BET proteins and epigenetic regulation. *Nat Commun* 2014; 5:5418.
121. Gjoksi B, Ghayor C, Siegenthaler B, *et al.* The epigenetically active small chemical *N*-methyl pyrrolidone (NMP) prevents estrogen depletion induced osteoporosis. *Bone* 2015; 78:114–121.
122. Brown JD, Lin CY, Duan Q, *et al.* NF-kappaB directs dynamic super enhancer formation in inflammation and atherogenesis. *Mol Cell* 2014; 56:219–231.
123. Jahagirdar R, Attwell S, Marusic S, *et al.* RVX-297, a BET bromodomain inhibitor, has therapeutic effects in preclinical models of acute inflammation and autoimmune disease. *Mol Pharmacol* 2017; 92:694–706.
124. Nicodeme E, Jeffrey KL, Schaefer U, *et al.* Suppression of inflammation by a synthetic histone mimic. *Nature* 2010; 468:1119–1123.
125. Chen TH, Weber FE, Malina-Altzinger J, Ghayor C. Epigenetic drugs as new therapy for tumor necrosis factor-alpha-compromised bone healing. *Bone* 2019; 127:49–58.
126. Miguel BS, Ghayor C, Ehrbar M, *et al.* *N*-Methyl pyrrolidone as a potent bone morphogenetic protein enhancer for bone tissue regeneration. *Tissue Eng Part A* 2009; 15:2955–2963.
127. Ghayor C, Gjoksi B, Dong J, *et al.* *N,N* Dimethylacetamide a drug excipient that acts as bromodomain ligand for osteoporosis treatment. *Sci Rep* 2017; 7:42108.
128. Li Q, Liu R, Zhao J, Lu Q. *N*-methyl pyrrolidone (NMP) ameliorates the hypoxia-reduced osteoblast differentiation via inhibiting the NF-kappaB signaling. *J Toxicol Sci* 2016; 41:701–709.